KR20160102081A - 건강한 노화 및 장수를 예측하고 증진하기 위하여 ｆｏｘｏ３ａ 다형성 및 일배체형을 사용하는 방법 - Google Patents

건강한 노화 및 장수를 예측하고 증진하기 위하여 ｆｏｘｏ３ａ 다형성 및 일배체형을 사용하는 방법 Download PDF

Info

Publication number
KR20160102081A
KR20160102081A KR1020167022020A KR20167022020A KR20160102081A KR 20160102081 A KR20160102081 A KR 20160102081A KR 1020167022020 A KR1020167022020 A KR 1020167022020A KR 20167022020 A KR20167022020 A KR 20167022020A KR 20160102081 A KR20160102081 A KR 20160102081A
Authority
KR
South Korea
Prior art keywords
ser
longevity
foxo3a
aging
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020167022020A
Other languages
English (en)
Korean (ko)
Inventor
티모시 애치슨 돈론
브래들리 존 윌콕스
제이. 다비드 커브
Original Assignee
쿠아키니 메디컬 센터
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41669598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20160102081(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 쿠아키니 메디컬 센터 filed Critical 쿠아키니 메디컬 센터
Publication of KR20160102081A publication Critical patent/KR20160102081A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
    • C12Q2535/125—Allele specific primer extension
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020167022020A 2008-08-10 2009-08-10 건강한 노화 및 장수를 예측하고 증진하기 위하여 ｆｏｘｏ３ａ 다형성 및 일배체형을 사용하는 방법 Abandoned KR20160102081A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8772208P 2008-08-10 2008-08-10
US61/087,722 2008-08-10
PCT/US2009/053307 WO2010019519A2 (en) 2008-08-10 2009-08-10 Method of using foxo3a polymorphisms and haplotypes to predict and promote healthy aging and longevity

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020117005559A Division KR101649541B1 (ko) 2008-08-10 2009-08-10 건강한 노화 및 장수를 예측하고 증진하기 위하여 ｆｏｘｏ３ａ 다형성 및 일배체형을 사용하는 방법

Publications (1)

Publication Number Publication Date
KR20160102081A true KR20160102081A (ko) 2016-08-26

Family

ID=41669598

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020167022020A Abandoned KR20160102081A (ko) 2008-08-10 2009-08-10 건강한 노화 및 장수를 예측하고 증진하기 위하여 ｆｏｘｏ３ａ 다형성 및 일배체형을 사용하는 방법
KR1020117005559A Active KR101649541B1 (ko) 2008-08-10 2009-08-10 건강한 노화 및 장수를 예측하고 증진하기 위하여 ｆｏｘｏ３ａ 다형성 및 일배체형을 사용하는 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020117005559A Active KR101649541B1 (ko) 2008-08-10 2009-08-10 건강한 노화 및 장수를 예측하고 증진하기 위하여 ｆｏｘｏ３ａ 다형성 및 일배체형을 사용하는 방법

Country Status (9)

Country Link
US (3) US20110212447A1 (enExample)
EP (1) EP2324127B1 (enExample)
JP (1) JP5814119B2 (enExample)
KR (2) KR20160102081A (enExample)
CN (1) CN102177255B (enExample)
AU (1) AU2009282172B2 (enExample)
CA (1) CA2733597C (enExample)
DK (1) DK2324127T3 (enExample)
WO (1) WO2010019519A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160102081A (ko) * 2008-08-10 2016-08-26 쿠아키니 메디컬 센터 건강한 노화 및 장수를 예측하고 증진하기 위하여 ｆｏｘｏ３ａ 다형성 및 일배체형을 사용하는 방법
US8990135B2 (en) * 2010-06-15 2015-03-24 The Regents Of The University Of Michigan Personalized health risk assessment for critical care
CN103233001B (zh) * 2012-06-25 2016-11-02 西北农林科技大学 秦川牛FoxO1基因单核苷酸多态性分子标记的检测方法与应用
KR102017562B1 (ko) * 2013-03-13 2019-09-03 (주)아모레퍼시픽 미백 효능 물질의 스크리닝 방법
WO2017062751A1 (en) * 2015-10-08 2017-04-13 The Regents Of The University Of California Compounds and methods for promoting stress resistance
WO2018183353A1 (en) * 2017-03-27 2018-10-04 Cardax Pharma, Inc. Small molecule compounds to support healthy human aging
CN110915165B (zh) * 2017-05-12 2023-05-26 麻省理工学院 用于共享私有数据的计算机实现的方法和装置
WO2019156591A1 (en) * 2018-02-12 2019-08-15 Limited Liability Company "Gero" Methods and systems for prediction of frailty background
CN111235250A (zh) * 2020-03-31 2020-06-05 中国科学院昆明动物研究所 与健康老龄相关的关键通路及其外周血dna甲基化位点标志物和应用
CN115466321B (zh) * 2022-09-23 2024-03-22 南方医科大学珠江医院 FOXO3a-DRI肽段、其药物组合物及应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311018D0 (en) 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
US4998617A (en) 1986-09-15 1991-03-12 Laura Lupton Inc Facial cosmetic liquid make up kit
US5459039A (en) 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
ATE267877T1 (de) 1993-01-07 2004-06-15 Sequenom Inc Dns - sequenzierung durch massenspektronomie
US5593826A (en) 1993-03-22 1997-01-14 Perkin-Elmer Corporation, Applied Biosystems, Inc. Enzymatic ligation of 3'amino-substituted oligonucleotides
US5747282A (en) 1994-08-12 1998-05-05 Myraid Genetics, Inc. 17Q-linked breast and ovarian cancer susceptibility gene
US5709999A (en) 1994-08-12 1998-01-20 Myriad Genetics Inc. Linked breast and ovarian cancer susceptibility gene
US5710001A (en) 1994-08-12 1998-01-20 Myriad Genetics, Inc. 17q-linked breast and ovarian cancer susceptibility gene
US5753441A (en) 1994-08-12 1998-05-19 Myriad Genetics, Inc. 170-linked breast and ovarian cancer susceptibility gene
US5693473A (en) 1994-08-12 1997-12-02 Myriad Genetics, Inc. Linked breast and ovarian cancer susceptibility gene
EP0699754B2 (en) 1994-08-12 2009-08-12 The University of Utah Research Foundation Method for diagnosing a predisposition for breast and ovarian cancer
US5837495A (en) 1994-10-13 1998-11-17 Applied Research Systems Ars Holding N.V. DNA encoding interleukin-1 antagonist
CA2239733C (en) 1995-12-18 2001-04-03 Myriad Genetics, Inc. Chromosome 13-linked breast cancer susceptibility gene
US6673546B2 (en) 2000-08-11 2004-01-06 The Children's Medical Center Corporation Genetic loci indicative of propensity for longevity and methods for identifying propensity for age-related disease
US20040121407A1 (en) 2002-09-06 2004-06-24 Elixir Pharmaceuticals, Inc. Regulation of the growth hormone/IGF-1 axis
EP1413584B1 (en) 2002-10-21 2005-03-02 AXXAM S.r.l. Photoprotein with improved bioluminescence
US7932049B2 (en) 2002-12-23 2011-04-26 University Of Massachusetts Methods of identifying longevity modulators and therapeutic methods of use thereof
DE10311769A1 (de) 2003-03-18 2004-09-30 Bayer Healthcare Ag Testmethoden zur Bestimmung der intrazellulären Konzentration zyklischer Nukleotide
US20070105109A1 (en) 2003-07-02 2007-05-10 Geesaman Bard J Sirt1 and genetic disorders
WO2005007687A1 (en) 2003-07-09 2005-01-27 Dana-Farber Cancer Institute, Inc Compositions and methods for modulating ovarian follicular initiation
JP2005168463A (ja) 2003-12-15 2005-06-30 Chisso Corp カルシウム結合型発光蛋白質の保存方法等
US20060069049A1 (en) 2003-12-29 2006-03-30 President And Fellows Of Harvard College Methods and reagents related to foxo
CA2569079A1 (en) * 2004-06-03 2005-12-15 The Johns Hopkins University Methods of screening for cell proliferation or neoplastic disorders
US7622271B2 (en) 2004-07-26 2009-11-24 University Of Washington Identification of aging genes through large-scale analysis
US20070118398A1 (en) * 2005-11-18 2007-05-24 Flicker Technologies, Llc System and method for estimating life expectancy and providing customized advice for improving life expectancy
JP5292569B2 (ja) * 2006-11-10 2013-09-18 国立大学法人名古屋大学 抗老化転写因子活性化剤及びその利用
KR20160102081A (ko) * 2008-08-10 2016-08-26 쿠아키니 메디컬 센터 건강한 노화 및 장수를 예측하고 증진하기 위하여 ｆｏｘｏ３ａ 다형성 및 일배체형을 사용하는 방법

Also Published As

Publication number Publication date
CA2733597C (en) 2019-02-26
HK1158271A1 (en) 2012-07-13
CN102177255A (zh) 2011-09-07
US20130295566A1 (en) 2013-11-07
WO2010019519A3 (en) 2010-05-27
US20110212447A1 (en) 2011-09-01
JP2011530312A (ja) 2011-12-22
AU2009282172B2 (en) 2016-06-02
EP2324127A4 (en) 2012-06-13
DK2324127T3 (en) 2015-04-27
US20150337383A1 (en) 2015-11-26
AU2009282172A1 (en) 2010-02-18
CA2733597A1 (en) 2010-02-18
EP2324127A2 (en) 2011-05-25
KR101649541B1 (ko) 2016-08-19
JP5814119B2 (ja) 2015-11-17
EP2324127B1 (en) 2015-01-21
WO2010019519A2 (en) 2010-02-18
US12534761B2 (en) 2026-01-27
KR20110057147A (ko) 2011-05-31
CN102177255B (zh) 2015-12-16

Similar Documents

Publication Publication Date Title
KR101649541B1 (ko) 건강한 노화 및 장수를 예측하고 증진하기 위하여 ｆｏｘｏ３ａ 다형성 및 일배체형을 사용하는 방법
Walters et al. A new highly penetrant form of obesity due to deletions on chromosome 16p11. 2
Zabena et al. The FTO obesity gene. Genotyping and gene expression analysis in morbidly obese patients
Wheeler et al. Sequential use of transcriptional profiling, expression quantitative trait mapping, and gene association implicates MMP20 in human kidney aging
Hubacek et al. The FTO variant is associated with chronic complications of diabetes mellitus in Czech population
Nasiri et al. SIRT1 gene polymorphisms associated with decreased risk of atherosclerotic coronary artery disease
EP2094868A2 (en) Sirtuin polymorphisms and methods of use thereof
US20100255475A1 (en) Diagnostics and therapeutics for osteoporosis
US20030170678A1 (en) Genetic markers for Alzheimer's disease and methods using the same
Kordkheyli et al. Analysis of KLF7 and KLF5 transcription factors gene variants in coronary artery disease
Nair et al. Association analysis of common variants in FOXO3 with type 2 diabetes in a South Indian Dravidian population
US20070299025A1 (en) Method for Detecting the Risk of Cardiovascular Diseases Such as Acute Myocardial Infarction and Coronary Heart Disease By Analysing Defesin
HK1158271B (en) Method of using foxo3a polymorphisms and haplotypes to predict and promote healthy aging and longevity
Khodyrev et al. The analysis of association between type 2 diabetes and polymorphic markers in the CDKAL1 gene and in the HHEX/IDE locus
Sidiropoulou et al. Impact of vitamin D receptor gene variants on psoriasis vulgaris susceptibility and clinical phenotype in a Greek population
US20040023225A1 (en) Methods and compositions for identifying risk factors for abnormal lipid levels and the diseases and disorders associated therewith
US20100184839A1 (en) Allelic polymorphism associated with diabetes
EP1217080A2 (en) Methods, compositions and kits relating to cardiovascular disease
Hansen et al. The Rhesus Monkey: A Nonhuman Primate Model For T2DM-Associated Gene Screening. J Diabetes Metab 2: 150. doi: 10.4172/2155-6156.1000150 Page 2 of 7 Volume 2• Issue 7• 1000150 J Diabetes Metab ISSN: 2155-6156 JDM, an open access journal nucleotide and amino acid levels; c) 89 percent of the rhesus monkey genes are syngenically aligned with the corresponding human genes; and d) an extraordinary amount of physiological similarity exists between rhesus monkeys and humans [13]
US20080194419A1 (en) Genetic Association of Polymorphisms in the Atf6-Alpha Gene with Insulin Resistance Phenotypes
Misra Association between PRO12ALA polymorphism at the PPARγ2 gene and insulin sensitivity in South Indian population with type 2 diabetes mellitus
Wheeler et al. Sequential use of transcriptional profiling
WO2011004345A1 (en) Upstream binding protein 1 polymorphisms and their use for prognosing or diagnosing arterial blood pressure

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20160811

Application number text: 1020117005559

Filing date: 20110309

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20160912

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160922

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20170727

NORF Unpaid initial registration fee
PC1904 Unpaid initial registration fee